Modeling Approaches for Determination of Pharmacokinetics/Pharmacodynamics
Explore insights from Certara experts on how PK/PD modeling streamlines biologic drug development.
Certara2025 年 8 月 5 日
Breaking New Ground: EMA Qualification of the Simcyp® Simulator Ushers in a New Era for PBPK Modeling
The Simcyp Simulator receives EMA qualification—the first and only PBPK platform formally qualified for any…
Certara2025 年 8 月 5 日
Certara Simcyp® Simulator Becomes First and Only Software Platform to Receive EMA Qualification Opinion for PBPK Modeling
Certara announces that EMA has formally qualified the Simcyp® Simulator for use in regulatory submissions…
Certara2025 年 8 月 4 日
How Pharma Can Transition to Non-animal Studies for Investigational Drugs
Pharma companies can ease the transition to non-animal studies for investigational drugs by leveraging NAMs…
Certara2025 年 7 月 25 日
The end of animal testing? Transitioning to models is promising — but no silver bullet
The FDA has stated that the pharma industry must transition to using in vitro assays,…
Certara2025 年 7 月 21 日
